Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 246% above its 1-year average of 0.00, near the high end of its 1-year range (-0.01–0.00).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation.
Limited quarterly history available
Debt to Equity needs at least three reported quarters before a meaningful chart is shown.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
N/A
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 480 covered companies
CURRENT VS SECTOR MEDIAN
-98.39%
vs the sector median at left
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.38B
Debt to Equity Ratio
0.00
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Debt to Equity Ratio
0.01
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Debt to Equity Ratio
N/A
TTM Avg
6.73
3Y Avg
5.46
5Y Avg
3.96
Market Cap
$1.34B
Debt to Equity Ratio
0.34
TTM Avg
0.19
3Y Avg
0.15
5Y Avg
0.15
Market Cap
$1.33B
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$1.47B
Debt to Equity Ratio
0.03
TTM Avg
0.04
3Y Avg
0.07
5Y Avg
0.06
Market Cap
$1.48B
Debt to Equity Ratio
0.13
TTM Avg
0.11
3Y Avg
1.37
5Y Avg
1.37
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.38B | 0.00 | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.39B | 0.01 | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | 6.73 | 5.46 | 3.96 |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | 0.34 | 0.19 | 0.15 | 0.15 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | 0.00 | 0.00 | 0.00 | 0.00 |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 25.47 | 2.79 | 1.47 | 0.99 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 0.03 | 0.04 | 0.07 | 0.06 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.48B | 0.13 | 0.11 | 1.37 | 1.37 |
| Kardigan, Inc. (KARD)vs › | $1.27B | 0.02 | N/A | N/A | N/A |
Debt/Equity
0.00
Current Ratio
35.85
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | -0.01 |
